MedTrace Logo

Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects

NCT02266498 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2014-10-17

No results posted yet for this study

Summary

To assess the effect of a breakfast (40 g fat) on single dose pharmacokinetics of a 2.5 mg BIBB 515 dose in capsules as well as the tolerability of BIBB 515 BS capsules

Conditions

  • Healthy

Interventions

DRUG

BIBB 515 BS

OTHER

Standard breakfast (40 g fat)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-06-30
Primary Completion
1998-07-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02266498 on ClinicalTrials.gov